Standard Contracts
AMENDMENT #1 TO THEProcess Development and Manufacturing Agreement • August 13th, 2002 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This Amendment #1 to the Process Development and Manufacturing Agreement (the “Amendment”) is made and entered into on April 15, 2002 by and between ONYX Pharmaceuticals, Inc., a Delaware Corporation having its principal place of business at 3031 Research Drive, Richmond, California 94806 (“ONYX”), and XOMA (US) LLC, a Delaware limited liability company (“XOMA”) with offices at 2910 Seventh Street, Berkeley, California 94710. ONYX and XOMA are sometimes referred to herein individually as a “Party” and collectively as “Parties.”
